Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Stem Cell Reports ; 18(3): 613-617, 2023 03 14.
Artículo en Inglés | MEDLINE | ID: mdl-36827977

RESUMEN

We outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies.


Asunto(s)
Medicina Regenerativa , Japón
3.
PLoS One ; 9(1): e84998, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24416332

RESUMEN

INTRODUCTION: International norms and ethical standards have suggested that compensation for research-related injury should be provided to injured research volunteers. However, statistical data of incidence of compensation claims and the rate of awarding them have been rarely reported. METHOD: Questionnaire surveys were sent to pharmaceutical companies and medical institutions, focusing on industry-initiated clinical trials aiming at new drug applications (NDAs) on patient volunteers in Japan. RESULTS: With the answers from pharmaceutical companies, the incidence of compensation was 0.8%, including 0.06% of monetary compensation. Of the cases of compensation claims, 99% were awarded. In turn, with the answers from medical institutions, the incidence of compensation was 0.6%, including 0.4% of serious but not death cases, and 0.04% of death cases. Furthermore, most claims for compensation were initiated by medical institutions, rather than by the patients. On the other hand, with the answers from clinical trial volunteers, 3% of respondents received compensations. These compensated cases were 25% of the injuries which cannot be ruled out from the scope of compensation. CONCLUSION: Our study results demonstrated that Japanese pharmaceutical companies have provided a high rate of compensation for clinical trial-related injuries despite the possibility of overestimation. In the era of global clinical development, our study indicates the importance of further surveys to find each country's compensation policy by determining how it is being implemented based on a survey of the actual status of compensation coming from statistical data.


Asunto(s)
Compensación y Reparación , Industria Farmacéutica/economía , Voluntarios Sanos/legislación & jurisprudencia , Revisión de Utilización de Seguros/economía , Heridas y Lesiones/economía , Ensayos Clínicos como Asunto , Industria Farmacéutica/ética , Industria Farmacéutica/estadística & datos numéricos , Drogas en Investigación/efectos adversos , Humanos , Revisión de Utilización de Seguros/ética , Revisión de Utilización de Seguros/estadística & datos numéricos , Japón , Encuestas y Cuestionarios , Heridas y Lesiones/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA